Treatment of Hyperlipidemia in the Nephrotic Syndrome: The Effects of Pravastatin Therapy

American Journal of Kidney Diseases

Volumn 22, Issue 1, 1993, Pages 143-150

  Spitalewitz, Samuel ^a,b,c   Porush, Jerome G ^a,b,c   Cattran, Daniel ^a,b,c   Wright, Noel ^a,b,c  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c Suite 644 48073   (United States)

Author keywords

Hyperlipidemia; nephrotic syndrome; pravastatin

Indexed keywords

CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE CLEARANCE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; MALE; NEPHROTIC SYNDROME; PROTEINURIA; TABLET;

EID: 0027200358     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(12)70180-4     Document Type: Article

References (46)

1. The hyperlipidemia of the nephrotic syndrome: Relation to the plasma albumin concentration, oncotic pressure and viscosity
2. Management of hyperlipidemia of kidney disease
3. The nephrotic syndrome and ischemic heart disease
4. Increased incidence of coronary heart disease associated with combined elevation of serum triglycerides and cholesterol concentrations in the nephrotic syndrome in man
5. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
6. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
7. Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies
8. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
9. Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients
10. Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy stage IV-V
11. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
12. Effects on an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia
13. HmG-CoA reductase inhibitors for treatment of hypercholesterolemia
14. Cholesterol and lipids in renal disease
15. Glomerular structures and lipids in progressive renal disease
16. Therapeutic implications of lipid-lowering agents in the progression of renal disease
17. Rationale and management of hyperlipidemia of the nephrotic syndrome
18. Efficacy and safety of pravastatin in patients with primary hypercholesterlemia.11
19. Pravastatin vs
20. Therapy of hypercholesterolemia with pravastatin: A new HmG-CoA reductase inhibitor
21. Lipoprotein-cholesterol distributions in selected North American populations: The lipid research clinics program prevalence study
22. Lipid Research Clinics Manual of Laboratory Operations
23. Lipoid nephrosis in 31 adult patients: Renal biopsy by light, electron and fluorescence microscopy with experience in treatment
24. Does the nephrotic syndrome increase the risk of cardiovascular disease?
25. Cardiovascular disease and the nephrotic syndrome: The other side of the coin
26. Ischaemic heart-disease as a complication of nephrotic syndrome
27. Status of the coronary arteries in the nephrotic syndrome
28. Lipids and progressive kidney disease
29. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome
30. Determinants of progressive renal disease in diabetes mellitus
31. The effects of lovastatin in hyperlipidemic patients with nephrotic syndrome
32. Treatment of the hyperlipidemia of the nephrotic syndrome: A controlled trial
33. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidemia of nephrotic syndrome
34. Fifteen year mortality in coronary drug project patients: Long term benefit with niacin
35. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
36. Fibric acids: Effects on lipids and lipoprotein metabolism
37. Complications during clofibrate treatment of nephrotic syndrome hyperlipoproteinemia
38. Treatment of nephrotic hyperlipoproteinemia with gemfibrizol
39. Influence of probucol on cholesterol and lipoprotein metabolism in man
40. Probucol inhibits oxidative modification of low density lipoprotein
41. Beyond cholesterol
42. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome
43. Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism
44. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria
45. Treatment of nephrotic syndrome hyperlipidemia with simvastatin
46. Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidemia